期刊文献+

治疗骨质疏松促进骨形成药物 被引量:1

Inducing bone formation drugs for osteoporosis
下载PDF
导出
摘要 一、OPG-OPGL-RANK系统与骨质 疏松新药物的开发 护骨素(osteoprotegrin,OPG)也称破骨细胞抑制因子(OCIF)是由成骨细胞与骨髓基质细胞产生的一种与肝素结合的分泌糖蛋白,属于TNF受体(TN-FR)家族的可溶性受体.护骨素配体(OPGL)又称RANKL或破骨细胞分化因子(ODF),是成骨细胞上的跨膜蛋白.
作者 郭世绂
出处 《中国骨肿瘤骨病》 2003年第2期69-72,78,共5页 Chinse Journal Of Bone Tumor And Bone Disease
  • 相关文献

参考文献15

  • 1[1]Mundy GR. Direction of drug discovery in osteoporois. Ann Rev Med,2002,337 - 354.
  • 2[2]Kostenuik PJ, Shalhoub V. Osteoprotegrin:a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des, 2001,7: 613 - 635.
  • 3[3]Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegrin (OPGL) directly activates mature osteoclasts. J Cell Biol, 1999,145:527- 538.
  • 4[4]Hirano T, BurrTB, Turner CH, et al. Anabolic effects of human biosynthetic parathyroid hormone fragment( 1 ~ 34) LY 333334 on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res,1999,14:536 - 545.
  • 5[5]Cann CE,Roe EB,Sanehez SD,et al. PTH effects in the femur envelope- specific responses by 3DQCT in postmenopausal women. J Bone Miner Res, 1999,14( Suppl. 1 ) S137.
  • 6[6]Reginster JY. Stromtium ranelate in osteoporosis. Current Pharmaceutic Design, 2002,8:1907 - 1916.
  • 7[7]Marie PJ, Ammann P, Boivin G, et al. Mechanisms of action and therapeutic potential of stromtium in bone. Calcified Tissue Interm, New york: Springer- Verlag Inc,2001.
  • 8[8]Carverzasio J, Palmer G, Bonjour JP. Fluoride: mode of action. Bone,1998,6:585 - 589.
  • 9[9]Ringe JD, Meunier PJ. What is the future for fluoride in the treatment of osteoporosis? Osteoporos Int 1995,5:71 - 74.
  • 10[10]Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science, 1999,286:1946- 1949.

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部